NecstGen

Leiden, NL
AAV Lentiviral Cell Therapy
Program data pending ClinicalTrials.gov matching · Last scored 2026-04-29
78.1
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ○ Press ✓ EMA GMP (1) ○ MHRA GMP

Quick Facts: NecstGen

Signal Score
78.1/100 (as of 2026-04-29)
Quality Compliance
100.0/100 — No FDA inspection records found for this manufacturer
Headquarters
Leiden, NL
Modalities
AAV, Lentiviral, Cell Therapy
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About NecstGen

Dutch CGT CDMO focused on clinical manufacturing.

Signal Score & Pillar Breakdown

Quality Compliance 100.0
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Source: FDA Data Dashboard
No FDA inspection records found for this manufacturer · Quality score requires FDA inspection data
FDA InspectionsNo US records on file
EMA GMP Certificates1 on record
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 58.0
1 manufacturing site: Leiden, Netherlands
Modalities: AAV, Lentiviral, Cell Therapy
Capacity assessment: 58.0/100
Sites: Leiden, Netherlands
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
1 manufacturing site: Leiden, Netherlands
Modalities: AAV, Lentiviral, Cell Therapy
Capacity assessment: 58.0/100

NecstGen EMA GMP Compliance 1 certificates

2025-11
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
NL/H 25/2055354 NECSTGEN Therapies Netherlands 2025-11-11 COMPLIANT
Source: EMA EudraGMDP · Retrieved Jul 04, 2026

Frequently Asked Questions About NecstGen

Does NecstGen hold EMA or MHRA GMP certificates?
CDMO Signal tracks 1 EMA GMP certificate for NecstGen.
What is NecstGen's CDMO Signal Score?
NecstGen has a Signal Score of 78/100, based on quality, operations, financial stability, and capacity data.
Evaluating NecstGen for a manufacturing program?
Use the free AI matchmaker to compare NecstGen against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs → Lentiviral CDMOs → Cell Therapy CDMOs →

Similar CDMOs

Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
Signal Score: 72.8
AAV, Lentiviral, Cell Therapy, mRNA, Monoclonal Antibody, Recombinant Protein
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 80.6
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein
OmniaBio
Hamilton, ON
Signal Score: 79.5
AAV, Lentiviral, CAR-T, Cell Therapy
Lonza
Basel, Switzerland
Signal Score: 78.2
AAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein